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Abstract
Background:  The ErbB2/Her2/Neu receptor tyrosine kinase is amplified in ~30% of human breast cancers.
Phosphorylation of the translation initiation factor, eIF2 inhibits global protein synthesis and activates a stress signaling
and growth suppressive program. We have shown that forced phosphorylation of eIF2 can suppress head and neck,
colorectal carcinoma and multiple myeloma tumor growth and/or survival. Here we explore whether ErbB2 modulates
eIF2 phosphorylation and whether forced phosphorylation of the latter can antagonize ErbB2 deregulation of mammary
acinar morphogenesis.
Results: We tested whether ErbB2 signaling influenced eIF2 signaling and whether enhanced phosphorylation of the
latter affected ErbB2-deregulated mammary acinar development. We obtained stable MCF10A cells overexpressing wild-
type (Wt) Neu/ErbB2 or a constitutively active (CA) variant via retroviral delivery or mammary tumor cells from MMTV-
Neu tumors. Western blotting, RT-PCR and confocal microscopy were used to analyze the effects of ErbB2 activation
on eIF2 signaling and the effect of the GADD34-PP1C inhibitor salubrinal. Wt- and MMTV-Neu cells formed aberrant
acini structures resembling DCIS, while CA-ErbB2 overexpression induced invasive lesions. In these structures we found
that CA-ErbB2 but not the Wt variant significantly down-regulated the pro-apoptotic gene CHOP. This occurred
without apparent modulation of basal phosphorylation of PERK and eIF2 or induction of its downstream target ATF4.
However, inhibition of eIF2 dephosphorylation with salubrinal was sufficient to inhibit Wt- and CA-ErbB2- as well as
MMTV-Neu-induced deregulation of acinar growth. This was linked to enhanced CHOP expression, inhibition of
proliferation, induction of apoptosis and luminal clearing in Wt-ErbB2 and to inhibition of cyclin D1 levels and subsequent
proliferation in CA-ErbB2 cells.
Conclusion: Depending on the strength of ErbB2 signaling there is a differential regulation of CHOP and eIF2
phosphorylation. ErbB2 uncouples in basal conditions eIF2 phosphorylation from CHOP induction. However, this signal
was restored by salubrinal treatment in Wt-ErbB2 expressing MCF10A cells as these DCIS-like structures underwent
luminal clearing. In CA-ErbB2 structures apoptosis is not induced by salubrinal and instead a state of quiescence with
reduced proliferation was achieved. Treatments that stabilize P-eIF2 levels may be effective in treating ErbB2 positive
cancers without severely disrupting normal tissue function and structure.
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Background
The receptor tyrosine kinase ErbB2 is over-expressed in
approximately 30% of human breast carcinomas [1-3]
and is a marker of poor prognosis [4]. Several transgenic
mouse models over-expressing human Her2 or rat Neu,
have highlighted the similarities between ErbB2/Neu-
mediated oncogenesis in murine models and human
breast cancer [5]. The effects of ErbB2 mediated oncogenic
transformation on breast epithelial biology have been
faithfully modeled using 3D reconstituted basement
membrane (Matrigel) culture systems [6,7]. Activation of
ErbB2 via receptor dimerization, generates tyrosine-phos-
phorylated recognition motifs, binding of SH2-domain
signaling proteins, that transmit proliferative/survival sig-
nals via multiple pathways, including the Shc- and/or
Grb2-activated Ras-Raf-MAPK and phosphatidylinositol-
3-kinase (PI-3 K) pathways (reviewed in [8]). Although
the mechanisms by which ErbB2 deregulates these pro-
mitogenic/survival signaling networks have been well
characterized, how ErbB2 signaling might influence the
cellular translation machinery to propagate its oncogenic
effects is still poorly understood.
The initiation factor eIF2 participates in a rate-limiting
step during the initiation of translation, namely the for-
mation of the ternary complex (TC) and AUG initiation
codon recognition. The role of eIF2 phosphorylation
during transformation by oncogenes like ErbB2 is poorly
understood. GTP-bound eIF2 interacts with the initiator
methionyl tRNA to form a ternary complex (TC) followed
by binding to the 40S ribosomal subunit. Phosphoryla-
tion of the  subunit of eIF2 at Ser-51 sequesters it in an
inactive GDP-bound complex with its GTP-exchange fac-
tor, eIF2B, resulting in attenuation of translation initia-
tion [9]. Phosphorylation of eIF2 can occur in response
to the accumulation of unfolded proteins in the ER lumen
to limit protein synthesis and relieve the ER load [10].
Still, gene expression is required for translating genes that
help cells cope with ER stress and also resume normal cell
function. Thus, eIF2 phosphorylation favors the transla-
tion of the transcription factor ATF4, which triggers a tran-
scriptional response to cope with ER and oxidative stress.
Further, in a negative feedback loop, eIF2 signaling
induces GADD34, the regulatory subunit of the serine/
threonine protein phosphatase 1 (PP1C), which directs
PP1C to dephosphorylate its substrate eIF2. This allows
cells to restore normal eIF2 phosphorylation and nor-
mal protein synthesis [11,12].
Cancer cells can enhance general and preferential transla-
tion of specific mRNAs coding forproteins that stimulate
proliferation or inhibit apoptosis (reviewed in [13]). For
example, ErbB2 can enhance c-Myc protein synthesis[14]
and increase Src translation via the Akt/mTOR/4EBP-1
pathway [15]. In addition, ErbB2 itself is post-transcrip-
tionally regulated [16-18]. Further, Ras signaling, which
ErbB2 can activate, can cause robust recruitment of
mRNAs for efficient translation even if transcription of the
same mRNAs is not enhanced [19]. Thus, increased trans-
lation of multiple mRNAs may allow oncogenes to rapidly
stimulate growth and/or adapt to growth/survival condi-
tions. However, how ErbB2 signaling cross talks with
eIF2 signaling has not been investigated in depth.
The role of eIF2 in oncogenesis has been established by
studies which demonstrated that overexpression of a non-
phosphorylatable mutant of eIF2[20] or a dominant-
negative eIF2 kinase [21] were sufficient to transform
cells. We showed that persistent phosphorylation of eIF2
by its upstream kinase PERK inhibits proliferation of
human mammary epithelial and squamous carcinoma
cells exerting growth suppressive effects in vivo [22,23].
We also showed that enhancement of eIF2 phosphoryla-
tion with the small molecule inhibitor of GADD34-PP1c
complex, salubrinal, can inhibit tumor growth of head
and neck carcinoma HEp3, colon carcinoma SW620 and
multiple myeloma RPMI8226 and U266B1 cells [23,24].
Here we sought to determine whether (i) signaling by
ErbB2 might modulate eIF2 phosphorylation and/or (ii)
whether enhancement of eIF2 phosphorylation might
limit growth by ErbB2 oncogenic signaling. We studied
these possibilities in MCF10A cells overexpressing wild
type or constitutively activated (CA) ErbB2 and in primary
cultures from MMTV-Neu mouse tumors. These onco-
genes lead to phenotypes similar to DCIS (WtErbB2-
MCF10A and MMTV-Neu) and invasive lesions
(MCF10A-CA-ErbB2) where hyper-proliferation and dis-
ruption of mammary acinar morphogenesis are observed.
Results
ErbB2/Neu disruption of normal mammary acinar 
morphogenesis
We generated MCF10A cells stably expressing either a
wild-type c-neu proto-oncogene (the rat homolog of the
human  Her2/c-erbB2  gene, henceforth Wt-ErbB2) or a
constitutively active variant of c-neu  (henceforth CA-
ErbB2). The CA-ErbB2 form has a single point mutation
in the trans-membrane domain of the receptor, which
results in a Val to Glu substitution at position 664 [25]
and increased transforming capacity compared to the
wild-type receptor [26-28]. Control MCF10A cells (empty
vector), formed spheroids with a hollow lumen sur-
rounded by a polarized basal layer of cells in Matrigel (Fig.
1A,  panels a, d). In contrast, expression of Wt-ErbB2
resulted in much larger, lumen-filled acinar structures by
day 9 in Matrigel (Fig. 1A, panels b, e). These structures
although clearly disorganized and larger were confined
and did not show outward invasion into the surrounding
matrix. These resembled ductal carcinoma in situ (DCIS)
structures where there is loss of epithelial organizationBMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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but no invasion of the surrounding tissue[6,29] (Fig.
1Apanel b). Expression of CA-ErbB2, resulted in even
larger, highly disorganized, lumen-filled multi-acinar
structures (Fig. 1A, panels c, f), suggesting a dose-depend-
ent effect of ErbB2 signaling on deregulation of acinar
development. These structures frequently showed cells
invading the surrounding matrix (Fig. 1Apanel c). Thus,
the CA-ErbB2 expressing cells appear to be to some extent
more migratory and invasive, like observed in invasive
carcinomas [6,29]. Immunoblots confirmed that the Neu/
ErbB2 protein was highly expressed in both Wt and CA-
ErbB2 cell lines (Fig. 1B). Further, ErbB2 phosphorylation
at Y-1221 and Y-1222 residues, known to be auto-phos-
phorylated during homodimerization of ErbB2 receptors,
were readily detected [30]. The levels of total ErbB2 were
slightly higher in Wt- than CAErbB2 cells. Still ErbB2
phosphorylation at residues pTy1221/1222 was strong
(Fig. 1B). ErbB2 over-expression was functional since we
observed an approximately 6-fold increase in P-Ser 473 of
Akt, and a 2.4 fold increase in P-Erk 1/2 levels in CA-
ErbB2 cells compared to vector control (Fig. 1B), indicat-
ing that overexpression of ErbB2/Neu receptors initiated
Characterization of ErbB2 overexpression in normal MCF10A mammary epithelial cells Figure 1
Characterization of ErbB2 overexpression in normal MCF10A mammary epithelial cells. (A) Phase-contrast 
micrographs (a, b, c) or representative DAPI-stained equatorial confocal sections (d, e, f) of acinar structures formed from 
stable MCF10A cells infected with retrovirus expressing empty vector or the wild-type rat Neu/ErbB2 (Wt-ErbB2) or the con-
stitutively active V664E Neu/ErbB2 mutant (CA-ErbB2) after 8-9 days of growth in Matrigel. Scale bars = 20 m. (B) Western 
blots of whole-cell lysates from monolayer cultures of MCF10A cells expressing empty vector, Wt-ErbB2 or CA-ErbB2 con-
structs probed with the indicated antibodies to downstream targets of ErbB2 signaling. GAPDH was used as loading control.BMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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downstream mitogenic signaling. With this model that
provides defined pathways readouts and phenotypic end-
points we tested whether eIF2 signaling was modulated
by the oncogenes and whether forced enhancement of
eIF2 phosphorylation affects ErbB2 modulation of aci-
nar morphogenesis in this system.
Effect of ErbB2 activation on basal eIF2 phosphorylation 
and expression of ATF4 and CHOP/GADD153
Using the model described in Fig. 1 we tested whether
eIF2 signaling was modulated by ErbB2 overexpression.
We observed no significant modulation of phospho-
eIF2 or total eIF2 levels in either Wt or CA-ErbB2 cells
compared to control cells as measured by immunoblot-
ting (Fig. 2A). Although we observed a trend towards
ErbB2 overexpression does not modulate phospho-eIF2 signaling under basal growth conditions Figure 2
ErbB2 overexpression does not modulate phospho-eIF2 signaling under basal growth conditions. (A, B) West-
ern blots of whole-cell lysates from monolayer cultures of MCF10A cells expressing empty vector, Wt-ErbB2 or CA-ErbB2 
constructs for phospho-and total PERK (A, top panels) or phospho- and total eIF2 (A, bottom panels) or ATF4. Total eIF2 
or GAPDH was used as loading control respectively. Bottom panels depict relative intensities quantified by scanning densitom-
etry and normalized to vector control. The averages of three or more independent experiments are shown; ± SEM. (C) Equa-
torial confocal sections of 10-day vector control (a) or wild type (Wt) ErbB2/Neu (b) or constitutively activated (CA) ErbB2/
Neu (c) structures labeled with an anti-CHOP antibody (green) or DAPI nuclear stain (blue). Arrows point to CHOP-positive 
cells in the acinar structure. Scale bars = 25 m. (D) Graph showing the percentage of cells per acinar structure that stained 
positive for CHOP. Values are representative of four independent experiments performed on different days (8-10) of growth 
in Matrigel; mean ± SEM. Statistical significance was determined using the unpaired t-test with p < 0.05 defined as statistically 
significant. N.S - not significant.BMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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enhanced PERK phopshorylation in the CA-ErbB2 cells vs.
Wt-ErbB2 and -Gal cells it was not statistically significant
when comparing at least 4 independent experiments (Fig.
2A). In agreement, with these results, we found no signif-
icant changes in basal ATF4 protein levels between Wt or
CA-ErbB2 cells and control cells (Fig. 2B). Thus, ErbB2 sig-
naling in 2D mmonolayers does not seem to significantly
modulate the basal phosphorylation of PERK, eIF2 and
ATF4 expression for deregulation of acinar morphogene-
sis.
We next determined whether expression of the down-
stream target of eIF2 signaling CHOP/GADD153 might
be modulated by ErbB2 overexpression in MCF10A cells.
Acini that were grown for 8-10 days in Matrigel, when
luminal clearing is initiated and apoptosis is evident [31],
were stained for CHOP expression. As reported previously
[22], we could detect CHOP positive cells within vector
control acinar structures and the signal largely localized
within the central luminal space. We next used LSCM to
quantify the number of CHOP positive cells per acini. A
slight but statistically non-significant trend towards less
CHOP staining was observed in non-invasive WtErbB2
structures compared to control acini and this signal was
randomly localized in the acini, possibly due to the
already deregulated architecture of these structures (Fig.
2D). In contrast, invasive CA-ErbB2 cell aggregates
showed a statistically significant reduction in the number
of cells positively stained for CHOP (Fig. 2D). We con-
clude that increased ErbB2 signaling while not affecting
basal phosphorylation of PERK and eIF2 or ATF4 expres-
sion, appears to downregulate CHOP expression in the
more invasive structures induced by CA-ErbB2.
Salubrinal increases phospho-eIF2 levels and significantly 
restricts ErbB2-deregulated acinar growth
The downregulation of CHOP in CA-ErbB2 structures sug-
gested that perhaps ErbB2 signaling uncouples eIF2
phosphorylation from CHOP induction and its growth
inhibitory function. However, the cells might still be sen-
sitive to higher levels of eIF2 phosphorylation. Thus, we
next tested whether ErbB2 oncogenic signaling could be
counteracted upon forced eIF2 phosphorylation or
whether it might still bypass the growth inhibitory func-
tion of this pathway [23,32,33]. To this end we used Salu-
brinal, a recently discovered small molecule inhibitor
shown to disrupt the GADD34-PP1 phosphatase complex
[34] and persistently induce high P-eIF2 levels. Four
days after seeding in Matrigel cells were treated with a low
dose of salubrinal (10 g/ml) until days 8 or 10. Treat-
ment with salubrinal at 24 and 48 hrs did not compro-
mise cell viability (see additional File 1B) but negatively
affected growth of Wt and CA-ErbB2 acini in adhered
monolayer conditions (see additional File 1C). This effect
was much more striking in Matrigel, where we observed
that salubrinal treatment significantly reduced acinar size
and growth in Matrigel (Fig. 3A). Compared to untreated
controls, salubrinal-treated Wt-ErbB2 cells formed
smaller, more organized growth-arrested acini and also
appeared to restore to some extent their normal organiza-
tion. In CA-ErbB2 structures salubrinal treatment signifi-
cantly reduced overall acinar size but did not seem to
almost fully restore normal acinar architecture and block
local invasion. Salubrinal treatment did not grossly affect
the growth and organization of vector control acini,
although a slight reduction in overall size was observed
(Fig. 3A, D). We confirmed that treatment with this low
dose of salubrinal (10 g/ml) was sufficient to enhance
basal eIF2 phosphorylation (over 2.5-fold) in vector, Wt
and CA-ErbB2 cells, as early as 24 hrs after treatment and
which could be maintained with daily salubrinal treat-
ment up to 72 hrs (Fig. 3B). Attempts to detect enhanced
phopshorylation of eIF2 in 3D acini showed a general
staining pattern throughout the acini which was not spe-
cific for basal or luminal cells and enhancement through
tunicamycin showed an enhanced signal that could not be
specifically assigned to luminal or basal cells, making the
results based on staining intensity more difficult to inter-
pret (data not shown). To estimate the size differences
between 8-day old vector, Wt-ErbB2 and CA-ErbB2 acini,
two perpendicular acinar diameters were measured using
calibrated software [22] and the volumes of individual
acini were calculated, considering an ellipsoid morphol-
ogy (Fig. 3C). The large acinar size in Wt-ErbB2 and CA-
ErbB2 (Fig. 3C) was markedly reduced by persistent treat-
ment with salubrinal. Quantification of the distribution
of acinar sizes over several volume ranges showed that in
untreated vector controls, less than 5 percent of acini
exceeded the 0.5-1 × 10-3 mm3 volume range (Fig. 3D)
and salubrinal treatment maintained acinar size below
this range (Fig. 3D). In contrast, a large proportion
(between 10-40 percent) of untreated Wt and CA-ErbB2
acini exceeded the 0.5-1 × 10-3 mm3 volume range. Treat-
ment with salubrinal considerably reduced the frequency
of these larger acini and shifted the majority of acini
towards the smaller volume ranges (less than 0.5 × 10-3
mm3) (Fig. 3D). These findings demonstrate that ErbB2-
induced deregulation of mammary acinar development
can be suppressed by inhibiting eIF2 dephosphorylation
with salubrinal.
Differential proliferative and apoptotic responses to 
Salubrinal by Wt vs. CA-ErbB2 expressing acini
The decrease in acinar sizes observed with salubrinal
could result from decreased cell proliferation, increased
apoptosis or a combination of both. To test whether salu-
brinal caused a reduction in cell proliferation, vector, Wt
and CA-ErbB2 acini were treated with salubrinal from day
4-10 in Matrigel, fixed and stained for Ki-67 (proliferation
marker). The percentage of Ki-67 positive cells per acinusBMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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was estimated using standard immunofluorescence and
LSCM [22]. Untreated vector acini showed Ki-67 positive
cells mainly located in the basal layer of epithelial cells
(Fig. 4A, panel a) and this was not affected by Salubrinal
treatment (Fig. 4A, panel b) suggesting that the slight
decrease in vector acini size is not attributable to reduced
proliferation. CA-ErbB2 overexpression caused a noticea-
ble increase in the percent of Ki67 positive cells compared
to empty vector control acini (Fig. 4A, panels c, e and 4B).
In all cases Ki67 positive cells were found both in the
outer rim as well as among the cells occupying the central
luminal space (Fig. 4A, panel c, e). Salubrinal treatment
of Wt-ErbB2 acini caused a statistically significant reduc-
tion in Ki67 (S-phase marker) and phospho-H3 (G2/M
marker) staining at day 6 of acinar growth, suggesting an
initial inhibition of proliferation (Fig. 4B, right and left
panels). However, these differences disappeared at day 8
and day 10 (Fig. 4B-C), suggesting that at these time
points salubrinal only marginally impacts proliferation;
we could also detect smaller sized acini still containing
Salubrinal increases basal phospho-eIF2 levels and significantly limits ErbB2-induced acinar growth Figure 3
Salubrinal increases basal phospho-eIF2 levels and significantly limits ErbB2-induced acinar growth. (A) Phase-
contrast micrographs of control and ErbB2-expressing acini untreated (top panels) or treated with salubrinal (10 g/ml) from 
Day 4-day 10 in Matrigel (bottom panels). Note the reduced acinar size of salubrinal treated ErbB2-expressing acini. Scale bars 
= 60 m. (B) Western blots showing the increase in phospho-eIF2 levels in empty vector, Wt-ErbB2 or CA-ErbB2 cells 
untreated or treated with salubrinal under adhered monolayer conditions for the indicated time points. Total eIF2 was used 
as loading control. (C) Acinar volume was quantified on day 8 in Matrigel after daily treatment with salubrinal (day 4 onwards) 
for vector, Wt-ErbB2 or CA-ErbB2 acini. Acinar volume was estimated by measure two perpendicular diameters per acinus, 
assuming an ellipsoid structure. Between 50-100 acini were quantified and results are representative of experiments repeated 
at least three times. Statistical significance was determined using the unpaired t-test with p < 0.05 defined as statistically signifi-
cant. (D) Graphs showing the distribution of acinar sizes over several volume ranges to depict the increase in acinar size upon 
ErbB2 activation, mean ± SD. Note that salubrinal treatment causes a shift in the percentage of acini falling within the smaller 
size ranges.BMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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many positively stained cells (Fig. 4A-dinset, DAPI chan-
nel and 4C). In contrast, a statistically significant decrease
in Ki-67 staining was observed in CA-ErbB2 acini (Fig.
4C). Thus, it appears that both wt-ErbB2 and CA-ErbB2
are susceptible to salubrinal inhibition of proliferation,
except that this effect is only observed during early phases
of acinar development in wt-ErbB2 cells and throughout
the growth phases for CA-ErbB2 cells.
In Wt-ErbB2 acini decreased acinar size could only be par-
tially explained by reduced proliferation in response to
salubrinal treatment. Thus, we tested whether apoptosis
was being modulated by sustained eIF2 phosphoryla-
tion. In this case cleaved caspase-3 staining was used as a
marker of apoptosis [22]. Our results revealed that sus-
tained treatment with salubrinal resulted in a significant
increase in cleaved caspase-3 positive cells that localized
Induction of eIF2 phosphorylation by salubrinal inhibits ErbB2-induced hyperproliferation Figure 4
Induction of eIF2 phosphorylation by salubrinal inhibits ErbB2-induced hyperproliferation. (A) Representative 
confocal images of equatorial cross-sections through day 10 vector control, wild type and constitutively active ErbB2 acini 
stained for Ki-67 (red) or the corresponding images stained with DAPI (blue). Untreated acini (panels a, c and e) and salubri-
nal treated acini (panels b, d and f). Note Ki-67-positive cells in the outer basal layer of cells in untreated vector control acini 
(outlined in dotted lines in some structures where edges are not obvious) compared to those occupying the central luminal 
space in untreated ErbB2-over-expressing acini. Scale bars = 40 m. Inset (panel d) depicts a smaller salubrinal-treated Wt-
ErbB2 acinus with many Ki-67 positive cells. (B) Graph showing distribution of the percentage of wt-ErbB2 cells per acinus 
that stained positively for Ki-67 at days 6, 8 and 10 (left panel) or phospho-H3 at day 6 (right panel); horizontal red line indi-
cates the median. Statistical significance was determined using the unpaired t-test with p < 0.05 defined as statistically signifi-
cant. N.S - not significant. Salubrinal treatment significantly decreases the percentage of Ki-67 positive cells in WT-ErbB2 acini 
only early at day 6.(C) Graph showing distribution of the percentage of cells per acinus that stained positively for Ki-67 cells; 
mean ± SEM. Statistical significance was determined using the unpaired t-test with p < 0.05 defined as statistically significant. 
N.S - not significant. Note the increase in percentage of Ki-67 positive cells in untreated CA-ErbB2 expressing acini compared 
to vector controls. Salubrinal treatment significantly decreases the percentage of Ki-67 positive cells in CA-ErbB2 acini.BMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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mainly to the central luminal space in vector control and
Wt-ErbB2 acini (Fig. 5A, panels b, d) and at a lower fre-
quency along the periphery in CA-ErbB2 acini (Fig. 5A,
panel f). Quantification of the percentage of cleaved cas-
pase-3 positive cells per acinus revealed that vector and
Wt-ErbB2 acini displayed similar rates of apoptosis under
basal untreated conditions while constitutively active
ErbB2 signaling displayed approximately 1.5-fold less cell
death further highlighting the stronger potency of this
mutant ErbB2 receptor (Fig. 5B). Salubrinal treatment sig-
nificantly enhanced the number of cleaved caspase-3 pos-
itive cells/acini in all three-cell types, albeit to different
extents. In vector and in Wt-ErbB2 acini the induction was
between 5-8 fold. In contrast, in salubrinal-treated CA-
ErbB2 acini, the fold induction of apoptosis was much
lower (approximately 3-fold) compared to untreated
cells, although still statistically significant (Fig. 5B). Of
note is the fact that although salubrinal enhanced luminal
apoptosis in Wt-ErbB2 structures, this did not seem to
affect the basal layer of viable cells but rather accelerated
luminal apoptosis, a normal occurrence during acinar
development. Thus, these structures that resemble DCIS
can be forced into a more differentiated or normal archi-
tecture by enhancing eIF2 phosphorylation Salubrinal
Salubrinal treatment induces apoptosis and accelerates luminal clearing in control and wild type ErbB2 acini Figure 5
Salubrinal treatment induces apoptosis and accelerates luminal clearing in control and wild type ErbB2 acini. 
(A) Two representative confocal images of equatorial cross-sections of day 10 vector control, wild type and constitutively 
active ErbB2 acini stained for cleaved caspase-3 (c-casp-3; green) or DAPI (blue). Untreated acini (panels a, c and e) and salu-
brinal treated acini (panels b, d and f). Note increase in c-caspase-3 stained cells within the luminal space in salubrinal-treated 
vector and Wt-ErbB2 acini. Scale bars = 25 m. (B) Graph showing distribution of the percentage of cells per acinus that 
stained positively for c-caspase3; mean ± SEM. Statistical significance was determined using the unpaired t-test with p < 0.05 
defined as statistically significant. N.S - not significant.BMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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did not affect the levels of BimEL, a pro-apoptotic protein
implicated in lumen formation [7] (data not shown) indi-
cating that apoptosis might proceed via selective activa-
tion of other pro-apoptotic phospho-eIF2 targets or via
autophagic death [35]. Our results suggest that salubrinal
treatment can counteract the ErbB2-mediated deregula-
tion of morphogenesis in 3D-culture by inhibiting early
proliferation, accelerating apoptosis and enhancing lumi-
nal clearing in Wt-ErbB2 over-expressing cells. In CA-
ErbB2 cells, inhibition of proliferation is primarily
responsible for reduced acinar growth and size.
We next tested whether the effect of salubrinal was limited
to the MCF10A model. Treatment with salubrinal of con-
trol normal mammary epithelial cells from FVB mice were
grown in Matrigel. In these cells, like in parental MCF10A,
salubrinal had minor effects on morphogenesis in 3D
(not shown). Further, in agreement with our results in
MCF10A cells overexpressing ErbB2, MMTV-Neu cells
obtained from spontaneous tumors that arose in these
mice formed dramatically enlarged structures devoid of
proper tissue architecture and with a filled lumen (Fig. 6).
However, treatment with salubrinal strongly inhibited
expansion of these deregulated structures reducing their
size in a statistically significant manner and favoring cav-
itation and proper lumen formation (Fig. 6A).
Salubrinal-mediated inhibition of acinar growth correlates 
with increased expression of CHOP and reduced cyclin D1 
levels
We first tested whether salubrinal might affect total ErbB2
protein levels. Western blot analysis showed that salubri-
nal had no effect on ErbB2 protein expression or its down-
stream targets Akt and Erk1/2 (Fig. 7A and data not
shown) indicating that the growth inhibitory effect of
salubrinal is not due to a decrease in total ErbB2 or down-
stream target protein levels. Salubrinal did not modulate
phospho-Ser473-Akt (Fig. 7C) or phospho-T202/Y204-
Erk1/2 levels at 24, 72 or 96 hrs (data not shown), indi-
cating that its growth suppressive effects were not due to
reduced activation or non-specific regulation of these sig-
naling components.
Salubrinal normalizes the deregulated acinar morphogenesis of MMTV-Neu mammary tumor cells Figure 6
Salubrinal normalizes the deregulated acinar morphogenesis of MMTV-Neu mammary tumor cells. Single epi-
thelial cells isolated from MMTV-Neu mouse mammary tumors were grown in 3D organotypic/Matrigel cell culture over a 
period of 10 days. (A) Size of vehicle control (CTRL) and salubrinal 5 ug/ml treated acini was calculated following the equation 
[(Length × width2)/2 = acini volume (mm3)] and plotted; Mann Whitney test p < 0.0001, n = 30. (B) Representative confocal 
images of equatorial sections through control and salubrinal treated MMTV-Neu acini stained with DAPI at day 10 in Matrigel. 
Salubrinal treatment reverted the tumorigenic phenotype of MMTV-Neu acini by promoting formation of normal lumens in 
growth arrested acini (lower panel) as compared to untreated acini showing luminal filling and increased size (upper panels).BMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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CHOP induction is dependent of eIF2 phosphorylation,
mediates ER stress-induced growth arrest and apoptosis
and can be up-regulated by salubrinal treatment [34,36].
CHOP staining was used as surrogate phenotypic readout
for phospho-eIF2 signaling and the number of CHOP
positive cells per acinus was quantified using LSCM as in
Fig. 2. Our results showed a statistically significant
increase in the frequency of CHOP-positive cells in vector
and Wt-ErbB2 acini after salubrinal treatment (Fig. 7B). In
contrast, CA-ErbB2 acini were able to bypass the salubri-
nal-mediated induction of CHOP. These results indicate
that the increase in CHOP expression coincides with the
induction of acinar apoptosis in vector acini and Wt-
ErbB2 structures. In CA-ErbB2-expressing cells this
mutant oncogene appears to block apoptosis and this
associates with less CHOP induction. This suggests that
prolonged treatment with salubrinal might induce a state
of quiescence in these cells.
Salubrinal may restrict growth by increasing expression of CHOP and suppressing cyclin D1 levels Figure 7
Salubrinal may restrict growth by increasing expression of CHOP and suppressing cyclin D1 levels. (A) Western 
blots for total ErbB2, phospho-Ser473 and total Akt levels after 24 hr salubrinal treatment (10 g/ml) of cells grown in monol-
ayer conditions. GAPDH was used as loading control. (B) Graph showing quantification of the percentage of CHOP positive 
cells per acinus, mean ± SEM. Statistical significance was determined using the unpaired t-test with p < 0.05 defined as statisti-
cally significant. N.S - not significant. Note the modest increase in CHOP expression in salubrinal-treated vector control and 
Wt-ErbB2 acini but not in CA-ErbB2 acini. (C) Western blots (top panels) for cyclin D1 levels after 72 hr salubrinal treatment 
(10 g/ml)of cells grown in monolayer conditions. GAPDH was used as loading control, N.S-non-specific band. Bottom graph, 
Cyclin D1 protein levels were quantified by scanning densitometry and normalized to GAPDH.(D) Schematic depicting the 
growth-inhibitory effects of increased eIF2 phosphorylation on aberrant acinar morphogenesis induced by ErbB2.BMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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Cyclin D1 has previously been shown to be a major medi-
ator of ErbB2-induced tumor cell proliferation and onco-
genesis [37]. When compared to vector control MCF10A
cells, cyclin D1 levels were significantly increased in Wt
and to an even greater extent in CA-ErbB2 cells (Fig. 7C).
This paralleled the increased rates of proliferation in 3D
cultures (Fig. 4B). Cyclin D1 levels were previously shown
to be downregulated upon treatment with a derivative of
salubrinal (sal003) and by inducible activation of a
dimerizing Fv2E-PERK protein [34,36]. We thus deter-
mined whether reduced cell proliferation was partly
attributable to a salubrinal-induced decrease in cyclin D1
levels. We found that sustained salubrinal treatment for
72 hrs resulted in a 3.6-fold and approximately 1.9-fold
decrease in cyclin D1 protein levels in treated Wt-ErbB2
and CA-ErbB2 cells, respectively, compared to untreated
cells (Fig. 7C). This decrease in cyclin D1 was also evident
as early as 24 hrs post treatment (data not shown). We
conclude that sustained eIF2 phosphorylation results in
the induction of CHOP and downregulation of cyclin D1
which could further account for the reduced proliferation
and smaller acinar size in salubrinal-treated ErbB2 acini.
Discussion
We established a model where acquisition of phenotypes
that resembled DCIS or invasive carcinoma can be mim-
icked by expressing the Wt-ErbB2 and a CA-ErbB2, respec-
tively. In this model we set out to determine whether
ErbB2 over-expression was linked to modulation of eIF2
phosphorylation and downstream pathway induction.
Our results show that there is a dependence of ErbB2 sig-
naling on eIF2 phosphorylation to promote deregula-
tion of mammary acinar morphogenesis in 3D cultures.
We found that both WT- and CA-ErbB2 did not signifi-
cantly modulate basal PERK or eIF2 phosphorylation.
Consistently, the expression of an eIF2 downstream tar-
get ATF4 also remained unchanged. Conversly expression
of the ATF4 target gene CHOP, was decreased but only in
invasive CA-ErbB2 expressing structures. Possible expla-
nations for this uncoupling are that ATF4 activity may be
reduced by ErbB2 signaling, that other transcription fac-
tors that regulate CHOP expression, such as ATF6 [38]
might be inhibited by CA-ErbB2 or that this oncogene
induces the rapid degradation of CHOP protein. That
CHOP is down regulated by ErbB2 is similar to that
observed with Ras and consistent with its function in
inducing growth arrest and/or apoptosis [36,39]. Thus,
ErbB2 signaling may uncouple eIF2-ATF4 signaling from
the deleterious effects of CHOP.
We found that as opposed to normal MCF10A or mouse
MECs, ErbB2 overexpressing human or mouse (MMTV-
Neu) MECs were very sensitive to enhanced eIF2 phos-
phorylation. This was supported by the fact that Salubri-
nal treatment and increased eIF2 phosphorylation
strongly inhibited Wt- or CA-ErbB2 deregulation of
MCF10A acinar morphogenesis. This was also evident in
MMTV-Neu induced structures that cavitated and reduced
their size upon Salubrinal treatment. However, depending
on the intensity of ErbB2 signaling, salubrinal treatment
achieved inhibition of the deregulated acinar morphogen-
esis via different mechanisms. In Wt-ErbB2 over express-
ing acini, which resemble structures observed in DCIS,
salubrinal treatment was largely associated with early
inhibition of proliferation (days 4-6) that was lost at later
time points (days 8-10) of morphogenesis when a strong
induction of apoptosis was detected. Interestingly, this
apoptosis occurred mostly in the luminal population of
cells, stressing the specificity of this signal to the luminal
compartment. Notably, salubrinal treatment could accel-
erate the normal process of luminal clearing which fails to
occur during ErbB2 oncogenesis [7]. These results also
suggested that salubrinal did not randomly exert toxic
effects on all cells within the acini but that it rather accel-
erated luminal clearing without compromising the viabil-
ity of basal cells within these structures. The induction of
apoptosis also correlated with enhanced luminal cleaved
caspase-3 positive cells and enhanced CHOP induction.
Further, studies are required to elucidate the precise apop-
totic pathways that are activated by salubrinal treatment.
Together these findings suggest that ErbB2 positive cancer
cells in lesions like DCIS might be particularly sensitive to
therapeutic drugs that enhance eIF2 phosphorylation.
In CA-ErbB2 acinar structures, which resembled invasive
lesions, salubrinal treatment also strongly inhibited
growth but mainly through inhibition of proliferation.
Apoptosis although induced, was of a much lower magni-
tude. Activated ErbB2 cells showed stronger activation of
Akt signaling that was not affected by salubrinal treatment
(Figs. 1 and 6). This suggests that enhanced Akt signaling
might in part allow these cells to resist the growth-inhibi-
tory effects of salubrinal treatment possibly by entering a
state of quiescence. The decrease in cyclin D1 levels in CA-
ErbB2 cells was also of a lower magnitude compared to
Wt-ErbB2, suggesting that the growth arrest was not
entirely dependent on down-regulation of this cell cycle
protein. Total protein levels of phospho- or total ErbB2,
Akt and Erk1/2 were unchanged, highlighting the selective
and specific mode of action of salubrinal. However, we
can not rule out that other target genes for GADD34-PP1C
[40] might be affected by salubrinal. It will be important
to determine whether phospho-mimetic mutants of eIF2
or the use of the FV2E-PERK fusion protein also generate
the same effects as salubrinal.
We recently showed that chronic inhibition of eIF2
phosphorylation by PERK dominant negative mutants in
MCF10A cells results in acinar deregulation and hyper-
plastic benign growth in vivo [22]. Thus, perturbationsBMC Cell Biology 2009, 10:64 http://www.biomedcentral.com/1471-2121/10/64
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that ablate the growth inhibitory function of PERK-eIF2
signaling can favor benign tumor formation. Here we
show that preventing eIF2 dephosphorylation can
severely compromise the oncogenic effects of ErbB2 sign-
aling. Together these studies support the notion that
increases in eIF2 phosphorylation and signaling above a
certain threshold can be growth inhibitory in cancer cells.
Our data allows us to entertain the possibility that the
process of transformation requires cells to dynamically
remodel eIF2 phosphorylation status to favor survival
and cells compromised in the ability to do so (i.e. very
strong eIF2 phosphorylation) may be negatively
selected. For example, oncogene-induced senescence in
normal melanocytes requires eIF2 signaling [41]. It is
possible then that only those cells able to adapt the eIF2
pathway to their advantage, that is maintain a more plas-
tic remodeling of the eIF2 pathway without reaching
very high or persistent phospho-eIF2 levels, go on to be
transformed. We therefore predict that cells that escape
ErbB2-induced senescence, might co-opt eIF2 phospho-
rylation and downstream signaling for survival.
Conclusion
We conclude that while ErbB2 signaling does not seem to
significantly modulate eIF2 phosphorylation at Ser51
tumor cells overexpressing this oncogene are highly sensi-
tive to the effects of hyper-phosphorylated eIF2 levels. In
contrast, normal MECs are marginally sensitive to Salubri-
nal treatment. We recently showed that doses of salubri-
nal that have no effect on basal multiple myeloma
viability greatly sensitize these cells to bortezomib (Vel-
cade) treatment in conjunction or after bortezomib treat-
ment [24]. Our present work describes a previously
unrecognized approach for targeting the hyper-prolifera-
tion induced by ErbB2 via pharmacological activation of
eIF2 signaling. Therapeutic treatments targeting the
eIF2 pathway may prove, alone or in combination with
other targeted therapies, to be useful in the treatment of
cancers over-expressing ErbB2. This and the fact that salu-
brinal or more powerful derivates like Sal003 do not
appear to have significant toxicities in murine models
may warrant further investigation into whether Salubrinal
or similar molecules that target GADD34-PP1C could be
used to treat breast cancers with amplified ErbB2.
Methods
Cell culture and generation of stable cell lines
MCF10A cells and the culture conditions in 2D or 3D cul-
tures were described previously [22]. The retroviral vectors
pLXSN empty vector, pLXSN-NNeu (Wt rat Neu) and
pLXSN-Neu* (constitutively active rat Neu, with a 664
Val->Glu substitution) were obtained from Dr. Lisa Petti
(Albany Medical Center, Albany, NY) [25]. Retroviral
delivery of transgenes was done as described previously
[22]. Primary cultures of control normal mammary epi-
thelial cells from FVB mice or cells from MMTV-Neu trans-
genic mice (FVB) were prepared as described [42]. For
Salubrinal treatment in Matrigel, acini were treated with
10 g/ml of salubrinal dissolved in DMSO or equal vol-
ume of solvent control starting on Day 4 of growth in
Matrigel and added fresh daily until Day 10 of growth.
Reagents and Antibodies
Salubrinal was obtained from Calbiochem. Anti-phos-
pho-ErbB2 (pTy1221/1222), anti-phospho- and total
PERK (P-Thr 980) and eIF2 (P-Ser 51), anti-phospho-
Akt (Ser473), cyclin D1 and anti-cleaved caspase-3 were
from Cell Signaling (Danvers, MA). Anti-total ErbB2 and
anti-total Erk 1 was from BD Biosciences. Anti-ATF4, anti-
CHOP/GADD153 (sc-575), anti-GADD34 and anti-phos-
pho-Erk 1/2 were from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-Ki-67 was from Invitrogen (Carlsbad, CA)
and anti-GAPDH from Calbiochem. Secondary antibod-
ies were described previously[22].
Western analysis and viability assays
Cells were washed with ice-cold PBS, lysed in RIPA buffer
containing protease and phosphatase inhibitors (Roche)
and processed for immunoblot analysis as described pre-
viously [22]. Protein concentration was determined using
the Bradford reagent (Biorad). Cell viability was deter-
mined using a Trypan blue exclusion assay.
Immunofluorescence and Laser Scannin Confocal 
Microscopy (LSCM)
Processing of MCF10A cells grown in 3D Matrigel for 8-10
days was done as described previously [22]. For detection
of CHOP, the primary antibody was used at a concentra-
tion of 1:50 (Santacruz Biotechnology, sc-575). Confocal
images representing equatorial sections of acinar struc-
tures were acquired using standardized acquisition
parameters on a Leica TCS SP5 inverted confocal micro-
scope (Leica Microsystems, USA) with 40× or 63× objec-
tives. Phase contrast images of acini were captured using a
calibrated Nikon Eclipse TS100 microscope fitted with a
digital SPOT-RT camera and corresponding software
(Sterling Heights, MI). Acinar size was estimated as
described previously [22].
Statistical analyses
Statistics were performed using MS-Excel or GraphPad
Prism 5.0 software (San Deigo, CA) and P values were cal-
culated using one-way ANOVA followed by the Bonfer-
roni multiple comparison post test or the unpaired t test
with p < 0.05 considered statistically significant. N.S = not
significant.
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